Brian Scrivani is a partner in the Corporate Department and a member of the firm’s Mergers & Acquisitions Group and Private Equity Group. Brian advises private equity firms and public and private clients, with his practice focusing on leveraged buyouts and other private equity transactions, public company acquisitions, sales and divestitures and mergers-of-equals. Brian also advises boards of directors and special committees on corporate and securities law, fiduciary matters and corporate governance matters, including unsolicited offers, proxy contests and other activist defense matters.
Brian’s recent transactions include representing:
- Apollo Global Management in various matters
- Honeywell in the activist campaign by Third Point
- Kate Spade & Company in its acquisition by Coach, Inc.
- The Kraft Heinz Company in its proposed acquisition of Unilever
- The special committee of the Pilgrim’s Pride board of directors in its acquisition of Moy Park from JBS
- Qualcomm Incorporated in connection with its successful defense against the unsolicited offer and proxy fight from Broadcom and in the proposed acquisition of NXP Semiconductors
Brian was also involved in numerous notable transactions prior to joining Paul, Weiss, including advising:
- E. I. du Pont de Nemours and Company in its merger of equals with Dow Chemical Company, its proxy contest by Trian Partners, its spin-off of The Chemours Company (DuPont’s performance chemicals business), its sale of DuPont Performance Coatings (k/n/a Axalta, Inc.) to The Carlyle Group, and its acquisition of Danisco A/S by tender offer
- Express Scripts in its acquisition of WellPoint Inc.’s NextRx subsidiaries
- Gilead Sciences, Inc. in its acquisition of Pharmasset, Inc.
- Landis+Gyr AG in its acquisition by Toshiba Corporation
- News Corporation in its acquisition of Move, Inc.
- Twenty-First Century Fox in the spin-off of News Corporation, its media, entertainment and publishing businesses
Brian was named a “2019 Rising Star” in M&A by The Deal, and is recognized by The Legal 500 as a recommended practitioner in private equity buyouts.